

# Daniel L. Gillen, Ph.D.

Associate Professor  
Department of Statistics, University of California, Irvine  
2226 Bren Hall, Irvine, CA 92697-1250  
Email: dgillen@uci.edu  
Phone: 949.824.9862 Fax: 949.824.9863

---

## Research Interests

Survival analysis, longitudinal data analysis, clinical trials, sequential testing, epidemiologic methods

## Education

1998-2003, Ph.D., Biostatistics, University of Washington, Seattle, WA.  
1998-2001, M.S., Biostatistics, University of Washington, Seattle, WA.  
1995-97, B.S., Mathematics, Cal Poly State University, San Luis Obispo, CA.

## Positions

### Academic Appointments

2008 - present, Associate Professor, Department of Statistics, University of California, Irvine  
2004 - 2008, Assistant Professor, Department of Statistics, University of California, Irvine  
2003 - 2004, Assistant Professor, Department of Health Studies, University of Chicago

### Collaborative Research / Committees

August 1998 - 2003, Department of Nephrology, University of Washington and Puget Sound Healthcare System, Department of Veterans Affairs, Seattle, WA. Principal Investigator: Catherine Stehman-Breen, MD, MS  
July 2001 - 2003, Coronary Artery Risk Development in Young Adults (CARDIA) Study, Renal Research Group, Seattle, WA. Principal Investigator: David Siscovick, MD, MPH  
September 2001 - present, Cardiovascular Health Study (CHS), Renal Working Group, Seattle, WA. Principal Investigator: David Siscovick, MD, MPH  
September 2003 - present, Nephrolithiasis Working Group, Chicago, IL. Principal Investigator: Fred Coe, MD  
January 2005 - present, Genetic Epidemiology Research Institute (GERI), UC Irvine, CA. Principal Investigator: Hoda Anton-Culver, MD PhD  
May 2008 - present, Alzheimer Disease Research Center, Data and Statistics Core leader, UC Irvine, CA.

## Academic Awards and Scholarships

CORCLR Travel Award, University of California, Irvine (2005, 2006).  
NIH Travel Award, International Biometrics Conference (Cairnes, AUS; 2004).  
NIH Travel Award, ENAR Young Investigators Meeting (Pittsburgh, PA; 2004).  
WNAR Student Paper Competition, "Information growth in a family of weighted logrank statistics under interim analyses", 1<sup>st</sup> place written paper, 1<sup>st</sup> place oral presentation (2003).  
Outstanding Student in Biostatistics Award, School of Public Health, University of Washington (2003).

Donovan J. Thompson Award for excellence in applied and theoretical Biostatistics, Dept. of Biostatistics, University of Washington (2000).

NIH Cancer-Epidemiology-Biostatistics Training Grant (1999 - 2003).

### **Professional Memberships**

American Statistical Association (2003-present)

International Biometric Society (2002-present)

American Society of Nephrology (2004-present)

### **Professional Services**

#### Professional Organizations

Program Chair (WNAR), Joint Meetings of the American Statistical Association; Arlington, VA (2009)

Organizer and chair of invited paper session: "Statistical Issues in the Design, Evaluation, and Monitoring of Clinical Trials with Longitudinal and Survival Endpoints", ENAR; Tampa, FL (2006)

Chair, WNAR Regional Advisory Board (2006-present)

Local Organizer, WNAR 2007 Annual Meeting; UC Irvine, Irvine, CA (2008)

#### Associate Editor

*Journal of the American Statistical Association - Case Studies and Applications (2009-present)*

#### Statistics Journal Reviewer

*Journal of the American Statistical Association*

*Biometrics*

*Lifetime Data Analysis*

*Sequential Analysis*

*Journal of Biopharmaceutical Statistics*

#### Clinical Journal Reviewer

*Kidney International*

*Journal of the American Society of Nephrology*

*Environmental Health Perspectives*

*Journal of the American Medical Association*

### **Appointments, Advisory Boards and Review Committees**

Member, FDA Advisory Committee for Reproductive Health Drugs, Food and Drug Administration

Chair, Data Safety Monitoring Committee, Multicenter Trial of Galiximab in Combination with Rituximab, Biogen Idec

Member, Data Safety Monitoring Committee, Multicenter Clinical Trial of Efalizumab, Genetech Corporation  
 Member, Data Safety Monitoring Committee, START Multicenter Trial: , Merck KGaA  
 Chair, Data Safety Monitoring Committee, Multicenter Clinical Trial of Lumiliximab, Biogen Idec  
 Member, Data Safety Monitoring Committee, Multicenter Clinical Trial of SGN-40, Seattle Genetics  
 Member, Data Safety Monitoring Committee, Multicenter Clinical Trial of rhThrombin, Zymogenetics  
 Member, Data Safety Monitoring Committee, Chao Comprehensive Cancer Center, University of California, Irvine  
 Member, Scientific Advisory Panel: NIH-PA-02-153: *Translational Research for the Prevention and Control of Diabetes*

### Academic Service

Member, Executive Committee, Donald Bren School of Information and Computer Sciences, UCI (2009-present)  
 Member, External Relations Committee, Donald Bren School of Information and Computer Sciences, UCI (2008-09)  
 Member, Graduate Policy Committee, Donald Bren School of Information and Computer Sciences, UCI (2004-08)  
 Member, FTE Committee, Program in Public Health, UCI  
 Lecturer, Hematology/Oncology Fellows' Research Series, UCI  
 Member, Council on Faculty Welfare, University of California, Irvine (2006-09)

### Research

#### Published Work - Statistical Journals

1. **Gillen D.** and Emerson S., "Information growth in a family of weighted logrank statistics under interim analyses" *Sequential Analysis*, Vol. 24 (2005), pp. 1-22.
2. **Gillen D.** and Emerson S., "A note on  $P$ -values under group sequential testing and nonproportional hazards" *Biometrics*, Vol. 61 (2005), pp. 546-51.
3. Emerson S., Kittelson J., and **Gillen D.**, "Bayesian evaluation of group sequential clinical trial designs", *Statistics In Medicine*, Vol. 26, No. 7 (2007), pp. 1431-49.
4. **Gillen D.** and Emerson S., "Non-transitivity in a class of weighted logrank statistics under nonproportional hazards", *Statistics and Probability Letters*, Vol. 77, No. 2 (2007), pp. 123-130.
5. Emerson S., Kittelson J., and **Gillen D.**, "Frequentist evaluation of group sequential clinical trial designs", *Statistics In Medicine*, Vol. 26, No. 28 (2007), pp. 5047-80.
6. Haneuse S., Rudser K., and **Gillen D.** "Flexible Bayesian survival modeling of the non-stationary effect of a time-dependent covariate", *Biostatistics*, Vol. 9, No. 3 (2008), pp. 400-10.
7. Schildcrout J., Jenkins C., Ostroff J., **Gillen D.**, Harrell F., and Trost D. "Dynamic treatment effects in longitudinal analyses of clinical safety: Modeling approaches that permit valid inferences in the presence of common selection mechanisms", *Statistics In Medicine*, Vol. 27, No. 12 (2008), pp. 2248-66.
8. **Gillen D.** and Johnson W., Comment on The Nested Dirichlet Process, (*In press, Journal of the American Statistical Association*)
9. **Gillen D.**, "A Random Walk Approach for Quantifying Uncertainty in Group Sequential Survival Trials" , *Computational Statistics and Data Analysis*, Vol. 53, No. 3 (2009), pp. 603-620.

#### Published Work - Clinical Journals

1. Stehman-Breen C., **Gillen D.**, and Gipson D., "Prescription of hormone replacement therapy in postmenopausal women with renal failure." *Kidney International*, Vol. 56 (1999), pp. 2243-7.
2. Stehman-Breen C., Sherrard D., **Gillen D.**, and Caps M., "Determinants of type and timing of initial permanent hemodialysis vascular access." *Kidney International*, Vol. 57 (2000), pp. 639-45.

3. Alem A., Sherrard D., **Gillen D.**, Weiss N., Beresford S., Heckeberst S., Wong C., and Stehman-Breen C., "Increased risk of hip fracture among patients with end-stage renal disease." *Kidney International*, Vol. 58 (2000), pp. 396-9.
4. Wong C., Gipson D., **Gillen D.**, Emerson S., Koepsell T., Sherrard D., Watkins S., and Stehman-Breen C., "Anthropometric measures and risk of death in children with end-stage renal disease." *American Journal of Kidney Diseases*, Vol. 36, No. 4 (2000), pp. 811-9.
5. Stehman-Breen, C., Sherrard, D., Alem, A., **Gillen, D.**, Heckeberst, S., Wong, C., Ball, A., and Weiss, N., "Risk factors for hip fracture among patients with end-stage renal disease." *Kidney International*, Vol. 58 (2000), pp. 2200-5.
6. Gibson K., Caps M., **Gillen D.**, Bergelin R., Primozich J., and Strandness D., "Identification of factors predictive of lower extremity vein graft thrombosis." *Journal of Vascular Surgery*, Vol. 33 (2001), pp. 24-31.
7. Gibson K., Caps M., Kohler T., Hatsukami T., **Gillen D.**, Aldassy M., Sherrard D., and Stehman-Breen C., "Assessment of a policy to reduce placement of prosthetic hemodialysis access." *Kidney International*, Vol. 59 (2001), pp. 2335-45.
8. Mazhar A., Johnson R., **Gillen D.**, Stivelman J., Ryan M., Davis C., and Stehman-Breen C., "Risk factors and mortality associated with calciphylaxis in end-stage renal disease." *Kidney International*, Vol. 60 (2001), pp. 324-32.
9. Gibson, K., **Gillen, D.**, Caps M., Kohler T., Sherrard D., and Stehman-Breen C., "Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study." *Journal of Vascular Surgery*, Vol. 34 (2001), pp. 694-700.
10. Seliger, S., Weiss, N., **Gillen, D.**, Kestenbaum, B., Ball, A., Sherrard, D., and Stehman-Breen, C., "HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients." *Kidney International*, Vol. 47 (2002), pp. 384-7.
11. Wong C., Hingorani S., **Gillen D.**, Sherrard D., Watkins S., Brandt J., Ball A., and Stehman-Breen C., "Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease." *Kidney International*, Vol. 61 (2002), pp. 630-7.
12. Fung F., Sherrard D., **Gillen D.**, Wong C., Kestenbaum B., Seliger S., Ball A., and Stehman-Breen C., "Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients." *American Journal of Kidney Diseases*, Vol. 40 (2002), pp. 307-14.
13. Kestenbaum B., **Gillen D.**, Sherrard D., Seliger S., Ball A., and Stehman-Breen C., "Calcium channel blocker use and mortality among patients with end-stage renal disease." *Kidney International*, Vol. 61 (2002), pp. 2157-64.
14. Ball A., **Gillen D.**, Sherrard D., Weiss N., Emerson S., Seliger S., Kestenbaum B., and Stehman-Breen, C., "The risk of hip fracture among dialysis and renal transplant recipients." *JAMA*, Vol. 288 (2002), pp. 3014-8.
15. Seliger S., **Gillen D.**, Longstreth W. Jr, Kestenbaum B., and Stehman-Breen C., "Elevated risk of stroke among patients with end-stage renal disease." *Kidney International*, Vol. 64 (2003), pp. 603-9.
16. Stehman-Breen C., **Gillen D.**, Steffes M., Jacobs D., Lewis C., Kiefe C., and Siscovick D., "Racial and gender differences in early onset renal disease among young adults - the Coronary Artery Risk Development in Young Adults (CARDIA) Study." *Journal of the American Society of Nephrology*, Vol. 14, No. 9 (2003), pp. 2352-7.
17. Wasse H., **Gillen D.**, Ball A., Kestenbaum B., Seliger S., Sherrard D., and Stehman-Breen C., "Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients." *Kidney International*, Vol. 64 (2003), pp. 1455-61.
18. Kestenbaum B., Seliger S., Easterling T., **Gillen D.**, Critchlow C., Stehman-Breen C., Schwartz S., "Cardiovascular and thromboembolic events following hypertensive pregnancy." *American Journal of Kidney Diseases*, Vol. 42 (2003), pp. 982-9.
19. Seliger S., **Gillen D.**, Tirschwell D., Wasse H., Kestenbaum B., Stehman-Breen C., "Risk Factors for incident stroke among patients with end-stage renal disease." *Journal of the American Society of Nephrology*, Vol. 14 (2003), pp. 2623-31.
20. Kestenbaum B., Seliger S., **Gillen D.**, Wasse H., Young B., Sherrard D., Weiss N., Stehman-Breen C., "Parathyroidectomy rates among United States dialysis patients: 1990-1999." *Kidney International*, Vol. 65 (2004), pp. 282-8.
21. Seliger S., Siscovick D., Stehman-Breen C., **Gillen D.**, Fitzpatrick A., Bleyer A., Kuller L., "Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study." *Journal of the American Society of Nephrology*, Vol. 15, No. 7 (2004), pp. 1904-11.
22. Jani A., Al-Qamari A., Sapra B., Krauz L., Awan A., Kocherginsky M., **Gillen D.**, "Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy." *Clinical Prostate Cancer*, Vol. 3, No. 1 (2004), pp. 43-8.
23. Mittalhenkle A., **Gillen D.**, Stehman-Breen C., "Increased risk of mortality associated with hip fracture in the dialysis population." *American Journal of Kidney Diseases*, Vol. 44 (2004), pp. 672-9.

24. Kestenbaum B., Andress D., Schwartz S., **Gillen D.**, Seliger S., Jadav P., Sherrard D., Stehman-Breen C., "Survival following parathyroidectomy among United States dialysis Patients." *Kidney International*, Vol. 66 (2004), pp. 2010-6.
25. Williams J., Javaid B., Kadambi P., **Gillen D.**, Harland R., Thistlewaite J., Garfinkel M., Foster P., Atwood W., Millis J., Meehan S., Josephson M., "Leflunomide for polyomavirus type BK nephropathy" *New England Journal of Medicine*, Vol. 352, pp. 1157-8.
26. Vokes T., **Gillen D.**, Lovett J., Favus M., "Comparison of T-scores from different skeletal sites in differentiating post-menopausal women with and without prevalent vertebral fractures" *Journal of Clinical Densitometry*, Vol. 8 (2005), pp. 206-15.
27. **Gillen D.**, Worcester E., and Coe F., "Decreased renal function among adults with a history of nephrolithiasis: A study of NHANES III" *Kidney International*, Vol. 67 (2005), pp. 685-90.
28. Santry H., **Gillen D.**, and Lauderdale D., "Trends in bariatric surgical procedures" *JAMA*, Vol. 294 (2005), pp. 1909-17.
29. Seliger S., Longstreth W., Katz R., Manolio T., Fried L., Shlipak M., Stehman-Breen C., Newman A., Sarnak M., **Gillen D.**, Bleyer A., Siscovick D., "Cystatin C and subclinical brain infarction" *Journal of the American Society of Nephrology*, Vol. 16, No. 12 (2005), pp. 3721-7.
30. Fried L., Katz R., Sarnak M., Shlipak M., Chaves P., Jenny N., Stehman-Breen C., **Gillen D.**, Bleyer A., Hirsch C., Siscovick D., Newman AB., "Kidney function as a predictor of noncardiovascular mortality" *Journal of the American Society of Nephrology*, Vol. 16, No. 12 (2005), pp. 3728-35.
31. **Gillen D.**, Coe F., and Worcester E., "Nephrolithiasis and increased blood pressure among females with increased BMI" *American Journal of Kidney Diseases*, Vol. 46 (2005), pp. 263-9.
32. Smith J., Rudser K., **Gillen D.**, Kestenbaum B., Seliger S., Weiss N., McDonald R., Davis C., Stehman-Breen C., "Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System", *Transplantation*, Vol. 81, No. 2 (2006), pp. 175-80.
33. Josephson M., **Gillen D.**, Javaid B., Kadambi P., Meehan S., Foster P., Harland R., Thistlewaite R., Garfinkel M., Atwood W., Jordan J., Sadhu M., Millis M., Williams J., "Treatment of renal allograft polyoma BK virus infection with leflunomide", *Transplantation*, Vol. 81, No. 5 (2006), pp. 704-10.
34. Delfino R., Staimer N., **Gillen D.**, Tjoa T., Sioutas C., Fung K., George S., Kleinman M., "Personal and ambient air pollution is associated with increased exhaled NO in children with asthma" *Environ Health Perspect*, Vol. 114, No. 11 (2006), pp. 1736-43.
35. Vokes T., **Gillen D.**, Pham A., Lovett J., "Risk factors for prevalent vertebral fractures in black and white female densitometry patients." *Journal of Clinical Densitometry*, Vol. 10 (2007), pp. 1-9.
36. Worcester E., **Gillen D.**, Evan A., Parks J., Wright K., Trumbore L., Nakagawa Y., and Coe F., "Evidence that postprandial reduction of renal calcium reabsorption mediates the hypercalcuria of patients with calcium nephrolithiasis", *American Journal of Physiology - Renal Physiology*, Vol. 292, No. 1 (2007), pp. 66-75.
37. Stankus N., Hammes M., **Gillen D.**, and Worcester E., "African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III", *Urological Research*, Vol. 35, No. 2 (2007), pp. 83-7.
38. **Gillen D.**, Worcester E., and Coe F., Response to comments on Evidence that postprandial reduction of renal calcium reabsorption mediates the hypercalcuria of patients with calcium nephrolithiasis, *American Journal of Physiology -Renal Physiology*, Vol. 292, No. 1 (2007), pp. 66-75.
39. Delfino R., Staimer N., Tjoa T., **Gillen D.**, Kleinman M., Sioutas C., and Cooper D. Personal and ambient air pollution exposures and lung function decrements in children with asthma *Environ Health Perspect*, (In Press)
40. **Gillen D.**, Stehman-Breen C., Smith J., McDonald R., Warady B. Brandt J., and Wong C., "The survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation", (In Press, *American Journal of Transplantation*)
41. Meyskens F. Jr, McLaren C., Pelot D., Fujikawa-Brooks S., Carpenter P., Hawk E., Kelloff G., Lawson M., Kidao J., McCracken J., Albers C., Ahnen D., Turgeon D., Goldschmid S., Lance P., Hagedorn C., **Gillen D.**, and Gerner E. "Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial", *Cancer Prev Res*, Vol. 1, No. 1 (2008), pp. 32-38.
42. Delfino R., Brummel S., Wu J., Stern H., Ostro B., Lipsett M., Winer A., Street D., Zhang L., Tjoa T., and **Gillen D.** "The relationship of respiratory and cardiovascular hospital admissions to the southern California wildfires of 2003", *Occup Environ Med*, Vol. 66, No. 3 (2009), pp. 189-97.
43. Miller N., **Gillen D.**, Williams J. Jr, Evan A., Bledsoe S., Coe F., Worcester E., Matlaga B., Munch L., and Lingeman J. "A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque", *BJU Int.*, Vol. 103, No. 7 (2009), pp. 966-71.

44. McLaren C., Fujikawa-Brooks S., Chen W., **Gillen D.**, Pelot D., Gerner E., and Meyskens F. Jr., "Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas", *Cancer Prev Res*, Vol. 1, No. 7 (2008), pp. 514-21.
45. Chang J., Delfino R., **Gillen D.**, Tjoa T., Nickerson B., and Cooper D. "Repeated respiratory hospital encounters among children with asthma and residential proximity to traffic", *Occup Environ Med*, Vol. 66, No. 2 (2009), pp. 90-8.
46. Delfino R., Chang J., Wu J., Ren C., Tjoa T., Nickerson B., Cooper D., and **Gillen D.**, "Repeated hospital encounters for asthma in children and exposure to traffic-related air pollution near the home", *Ann Allergy Asthma Immuno*, Vol. 102, No. 2 (2009), pp. 138-44.
47. Sarsoza F., Saing T., Kayed R., Dahlin R., Dick M., Broadwater-Hollifield C., Mobley S., Lott I., Doran E., **Gillen D.**, Anderson-Bergman C., Cribbs D., Glabe C., and Head E. "A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain", *Acta Neuropathol* Apr 2009 (Epub).
48. Johnson M., Edwards R., Ghilardi A., Berrueta V., **Gillen D.**, Frenk C., and Masera O., "Quantification of carbon savings from improved biomass cookstove projects", *Environ Sci Technol*, Vol. 43, No. 7 (2009), pp. 2456-62.
49. Bergsland K., Coe F., **Gillen D.**, and Worcester E., "A test of the hypothesis that collecting duct calcium sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers", *Am J Physiol Renal Physiol*, Jul 2009 (Epub).

## Teaching

### *Course Development*

#### University of California, Irvine

*Statistical Methods II (STAT 211)*: The second quarter of a three quarter sequence in the theory and application of statistical methods for graduate students in statistics. This course covers the theory and application of generalized linear models. First offered Winter 2005.

*Introduction to Probability & Statistics III (STAT 120C)*: The third quarter of a three quarter sequence in mathematical statistics for upper division undergraduate students. This course develops the theory behind ANOVA, linear regression, and categorical data methods. First offered Spring 2005.

*Modern Data Analysis Methods (STAT 235)*: A one quarter course in the theory and application of modern statistical methods used in data analysis including resampling techniques, smoothing, cross-validation, and simulation as tool for evaluating these procedures. The course content is geared towards first year graduate students in statistics. First offered Fall 2007.

*Biostatistics (STAT 250)*: A one quarter course in the theory and application of statistical methods commonly used in public health research. The course content is geared towards first year graduate students in statistics. First offered Fall 2005.

### *Formal Teaching*

#### University of California, Irvine

Stat 120C – Introduction to Probability & Statistics III : Spring 2005, 2006, 2007, Department of Statistics, University of California, Irvine.

Stat 211 – Statistical Methods II (Generalized Linear Models) : Winter 2005, 2006, 2007, Department of Statistics, University of California, Irvine.

Stat 212 – Statistical Methods III (Analysis of Longitudinal Data) : Spring 2007, Department of Statistics, University of California, Irvine.

Stat 235 – Modern Data Analysis Methods : Fall 2007, Department of Statistics, University of California, Irvine.

Stat 250 – Biostatistics : Fall 2005, Department of Statistics, University of California, Irvine.

#### University of Chicago

HSD 324 – Survival Analysis : Spring 2004, Departments of Health Studies and Statistics, University of Chicago.  
 Clinical Research Training Program : Fall/Winter/Spring 2003-04, Departments of Health Studies and Statistics, University of Chicago.

California Polytechnic University, San Luis Obispo

Math 116 – College Algebra : Winter/Spring 1998, Department of Mathematics, Cal Poly State University, San Luis Obispo.

Math 100 – Beginning/Intermediate Algebra : Fall/Winter/Spring 1996 - 1998, Student Academic Services, Cal Poly State University, San Luis Obispo.

Math 116 – College Algebra : Summer 1996-97, Summer Institute, Cal Poly State University, San Luis Obispo.

*Shortcourses*

Summer Institute in Statistical Genetics, University of Washington, *Design, Monitoring, and Analysis of Clinical Trials*; Seattle, WA; June 2007.

Insightful Web-Based Training, *Design, Monitoring, and Analysis of Clinical Trials*; April and June 2007.

Cephalon, *Design, Monitoring, and Analysis of Clinical Trials*; Fraser, PA; November 2006.

Genentech, *Implementation of Group Sequential Methods Using S+SeqTrial*; San Francisco, CA; December 2006.

American Society of Nephrology Annual Conference, *Introduction to Biostatistics* (2000, 2001)

Department of Nephrology, Puget Sound Healthcare System, *An Introduction to SAS* (2001, 2002)

**Invited Talks and Seminars**

Academic Departments and Government Institutions

1. University of Washington, Department of Biostatistics, "A random walk approach to the design and monitoring of group sequential trials" (Seattle, WA; Feb 2007)
2. FDA, "Statistical issues in the analysis of oral contraceptive trials" (Washington, DC; Jan 2007)
3. Cal Poly State University, San Luis Obispo, Department of Statistics, "On the Analysis of Survival Data - Limitations of Commonly Used Methodology" (San Luis Obispo, CA; Dec 2006)
4. University of California, Riverside, Department of Statistics, "A random walk approach to the design and monitoring of group sequential trials" (Riverside, CA; Oct 2006)
5. University of California, Irvine, Department of Medicine Grand Rounds, "Design and Analysis of Clinical Studies with Time-Varying Effects: Case Studies and Examples" (Orange, CA; May 2006)
6. Vanderbilt University, Department of Biostatistics, "A random walk approach to the design and monitoring of group sequential trials" (Nashville, TN; Oct 2005)
7. NIH, NIAID, "Evaluation and monitoring of groups sequential trials under nonproportional hazards" (Washington, DC; July 2005).
8. University of California, Los Angeles, Department of Biostatistics, "A random walk approach to the design and monitoring of group sequential trials" (Los Angeles, CA; Feb 2005)
9. Brown University, Center for Statistical Sciences, "Issues in the design and analysis of group sequential survival trials" (Providence, RI; Nov 2004)
10. University of California, Irvine, Division of Epidemiology, "A joint longitudinal and survival model for flexibly incorporating nonproportional hazards" (Irvine, CA; Nov 2004)
11. Claremont McKenna College, Department of Mathematics, "When is enough, enough? The use of group sequential methods in clinical trials" (Claremont, CA; Oct 2004)
12. University of Wisconsin, Madison, Department of Biostatistics and Medical Informatics, "The use of weighted logrank statistics in group sequential trials" (Madison, WI; Apr 2004)

### National Meetings

1. WNAR, "On the use of prior information for flexibly monitoring group sequential survival trials" (Davis, CA; June 2008)
2. ENAR, "A constrained boundaries approach for monitoring time to event outcomes" (Washington, DC; March 2008)
3. ENAR, "A random walk approach to the design and monitoring of group sequential trials" (Tampa, FL; March 2006)
4. Joint Statistical Meetings, Session Chair - "Bayesian hierarchical modeling in biostatistics" (Minneapolis, MN; Aug 2005)
5. WNAR, "The design and analysis of group sequential survival trials: A random walk approach" (Fairbanks, AK; Jun 2005)
6. California Association of Regional Cancer Registries (CARCR) Research Symposium, "Methods for modeling time-varying covariate effects in cohort studies" (Newport Beach, CA; February 2005)
7. American Society of Nephrology, Invited lecture, "Perils and pitfalls in estimating renal function" (San Diego, CA; Nov 2003)
8. WNAR, Panel discussion on *Effective Teaching Practices* (Los Angeles, CA; Jun 2002).

### **Contributed Presentations at National and International Meetings**

1. American Society of Nephrology, "The Survival Advantage of Pediatric Recipients of a First Kidney Transplant among Children Awaiting Kidney Transplantation", (poster) (San Diego, CA; Nov 2006)
2. American Society of Nephrology, "Increased Risk of Thrombosis among Patients with End-Stage Renal Disease", (poster) (San Diego, CA; Nov 2006)
3. American Society of Nephrology, "Decreased renal function among adults with a history of nephrolithiasis: A study of NHANES III", (poster) (St. Louis, MO; Nov 2004)
4. American Society of Nephrology, "Nephrolithiasis and increased blood pressure among females with increased BMI", (poster) (St. Louis, MO; Nov 2004)
5. Joint Statistical Meetings, "A joint longitudinal and survival model for flexibly incorporating nonproportional hazards" (Toronto, CAN; Aug 2004).
6. International Biometric Conference, "Estimation of fixed time survival via random walks" (Cairnes, AUS; Jul 2004).
7. Joint Statistical Meetings, "Evaluating a clinical trial in the presence of non-proportional hazards" (San Francisco, CA; Aug 2003).
8. WNAR, "Information growth in a family of weighted logrank statistics under interim analyses" (Golden, CO; Jun 2003).
9. WNAR, "Non-transitivity in a class of weighted logrank statistics under non-proportional hazards" (Los Angeles, CA; Jun 2002).

### **Grant Funding**

- April 2009 - March 2011 National Institutes of Health (NCI - R03 CA135691)  
Title: Evaluation of Methods for Estimating Haplotype Effects in Survival Studies  
Role: PI
- April 2005 - March 2010 National Institutes of Health (NIA - P50 AG16573 )  
Title: Alzheimers Disease Research Center at the University of California, Irvine  
Role: Co-Investigator (Data and Statistics Core Director) with C. Cotman as PI
- January 2008 - December 2008 UCI ICS Fund for Excellence in Collaborative  
Title: Multiple Outputation for Inference Regarding Haplotype Effects in Survival Studies  
Role: PI
- September 2006 - August 2008 National Institutes of Health (NCI - CA123248)  
Title:Hypomorphic Mismatch Repair Gene Mutations And Single Molecule MSI  
Role: Co-PI with S. Lipkin and E. Chao
- June 2005 - April 2007 National Institutes of Health (EHS - ES11615)  
Title:Pediatric Asthma, Particulate Air Pollution and NO<sub>2</sub>  
Role: Co-Investigator with R. Delfino as PI
- June 2005 - May 2010 National Institutes of Health (NIDDK - PO1 DK56788)  
Title: Pathogenesis of Nephrolithiasis  
Role: Co-Investigator with F. Coe as PI
- September 2003 - August 2004 National Institutes of Health (NK30 HL04093)  
Title: Clinical Research Training Program  
Role: Co-Investigator with F. Coe as PI
- May 2003 - December 2003 National Institutes of Health (NHLBI - RO1 HL69719)  
Title: Group Sequential Methods for Longitudinal Data  
Role: Research Assistant with S. Emerson as PI